Artelo Biosciences, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Amounts below are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
Business context
Artelo is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system. It has no approved products and has not generated revenue.
- ART27.13: In the Phase 2a portion of the CAReS study for cancer-related anorexia; Phase 2a began in April 2023, with plans to expand to 40 patients.
- ART26.12: FABP5 inhibitor in regulatory-enabling studies, initially targeting chemotherapy-induced peripheral neuropathy. The company anticipated first-in-human studies in the second half of 2024, subject to study resources and regulatory review.
- ART12.11: CBD cocrystal in preclinical development for potential indications including anxiety, PTSD, and inflammatory bowel disease.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $1,585 | $1,078 | $3,572 | $2,598 |
| General and administrative expense | $1,029 | $1,316 | $3,118 | $4,213 |
| Total operating expenses | $2,614 | $2,394 | $6,690 | $6,811 |
| Net loss | $2,449 | $2,330 | $6,216 | $6,744 |
| Basic and diluted loss per share | $0.83 | $0.82 | $2.15 | $2.38 |
- Q3 operating expenses increased 9% year over year as higher R&D costs more than offset lower G&A costs. Nine-month operating expenses declined 2%, as lower G&A—primarily stock-based compensation—offset increased R&D spending.
- Other income, principally gains in fair value of trading securities, was $165 in Q3 and $474 for the nine months, compared with $64 and $67, respectively, in 2022. No income tax provision was reported.
- At September 30, cash and cash equivalents were $2.639 million and trading marketable securities were $10.225 million, for combined cash and marketable securities of approximately $12.864 million. Current assets were $13.428 million; current liabilities were $921,000; working capital was $12.507 million.
- Total liabilities were $921,000, including $32,000 of current operating lease liabilities; the filing reports no other debt. The company reported $15.499 million in total assets and $14.578 million in stockholders’ equity.
- Nine-month operating cash use was $5.611 million, investing activities provided $766,000, and financing activities provided $535,000. Cash and cash equivalents decreased by $4.249 million to $2.639 million.
Material changes, outlook, and risks
- Management said existing cash resources were expected to fund planned operations into the first quarter of 2025. Continuing beyond then requires additional capital through equity or debt offerings, licensing, or other sources; funding availability and sufficiency are not assured.
- The company has a $20 million equity line, subject to its terms, and had received $535,000 from issuing 306,666 shares under it through September 30. A $75 million shelf registration became effective in July 2023, subject to a limit of one-third of public float in any 12-month period. Subsequent to quarter-end, Artelo issued 26,605 shares for $33,000 under the equity line.
- UK R&D tax credits received were $1.206 million in the first nine months of 2023, versus $1.041 million in 2022. The filing warns that credits may be reduced or unavailable for certain clinical-trial spending outside the UK from April 2024, potentially increasing development costs.
- Key risks include ongoing losses and financing needs, potential shareholder dilution, clinical and regulatory uncertainty, reliance on third-party research and manufacturing providers, intellectual-property and licensing risks, controlled-substance regulation, and possible disruption from geopolitical events, economic conditions, or supply constraints. Research and development contracts may also require additional milestone payments; amounts are not clearly quantified in the filing.
- Management reported effective disclosure controls and procedures as of September 30, 2023, and no material change in internal control over financial reporting during the quarter. The company reported no material pending legal proceedings.
Important facts for investors to verify
- Whether the expected cash runway into Q1 2025 remains achievable given operating cash use, clinical spending, and actual financing activity.
- Current cash and marketable-securities balances, and the composition, liquidity, and valuation of the trading securities portfolio.
- CAReS Phase 2a enrollment, safety and efficacy updates, and whether ART26.12 regulatory-enabling studies remain on schedule for anticipated first-in-human work.
- Availability and terms of future financing, including use of the equity line or shelf registration, resulting dilution, and the impact of changes to UK R&D tax credits.
- Potential clinical-contract milestone commitments and any subsequent material developments not reflected in the September 30 financial statements.